Functional remodeling of macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma

被引：0
|
作者：
Han, Zhen [1 ,5 ]
Su, Ching-Yu [1 ,5 ]
Wu, Xiwei [2 ,5 ]
Qin, Hanjun [2 ,5 ]
Zain, Jasmine [3 ]
Rosen, Steven T. [3 ,5 ]
Querfeld, Christiane [1 ,3 ,4 ,5 ]
机构：
[1] City Hope Natl Med Ctr, Div Dermatol, Duarte, CA USA
[2] City Hope Natl Med Ctr, Dept Mol & Cellular Biol, Duarte, CA USA
[3] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA
[4] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA USA
[5] Beckman Res Inst, Duarte, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2021年 / 156卷
关键词：
Tumor microenvironment; PD1/PD-L1; blockade; lenalidomide; macrophage remodeling; CTCL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Prec-O2-04
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 50 条
  • [1] Reprogramming of tumor-associated macrophages with anti-PD-L1 & lenalidomide in cutaneous T cell lymphoma
    Han, Z.
    Su, C.
    Wu, X.
    Qin, H.
    Gunes, E.
    Rosen, S.
    Querfeld, C.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S119 - S119
  • [2] Reprogramming of PD-1+M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma
    Han, Zhen
    Wu, Xiwei
    Qin, Hanjun
    Yuan, Yate-Ching
    Schmolze, Daniel
    Su, Chingyu
    Zain, Jasmine
    Moyal, Lilach
    Hodak, Emmilia
    Sanchez, James F.
    Lee, Peter P.
    Feng, Mingye
    Rosen, Steven T.
    Querfeld, Christiane
    JCI INSIGHT, 2023, 8 (13)
  • [3] Reprogramming of PD1+M2-like tumor-associated macrophages with anti-PD-L1 and Lenalidomide in cutaneous T cell lymphoma.
    Han, Zhen
    Su, Chingyu
    Wu, Xiwei
    Qin, Hanjun
    Rosen, Steven T.
    Querfeld, Christiane
    CANCER RESEARCH, 2021, 81 (13)
  • [4] Anti-PD-L1 and lenalidomide enhance anti-tumor immunity in cutaneous T cell lymphoma through targeting PD1+M2-like tumor-associated macrophages
    Querfeld, Christiane
    Wu, Xiwei
    Qin, Hanjun
    Yuan, Yate-Ching
    Su, Chingyu
    Zain, Jasmine
    Feng, Mingye
    Rosen, Steven
    Han, Zhen
    EUROPEAN JOURNAL OF CANCER, 2023, 190 : S4 - S4
  • [5] Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial
    Querfeld, Christiane
    Chen, Lu
    Wu, Xiwei
    Han, Zhen
    Su, ChingYu
    Banez, Melissa
    Quach, Jeralyn
    Barnhizer, Tiffanie
    Crisan, Liliana
    Rosen, Steven T.
    Zain, Jasmine M.
    BLOOD, 2023, 142
  • [6] Anti-PD-L1 mAb reduces tumor growth in a mouse model of cutaneous T cell lymphoma
    Wu, X.
    Wang, K.
    Hwang, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S47 - S47
  • [7] Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment
    Xiong, Huizhong
    Mittman, Stephanie
    Rodriguez, Ryan
    Moskalenko, Marina
    Pacheco-Sanchez, Patricia
    Yang, Yagai
    Nickles, Dorothee
    Cubas, Rafael
    CANCER RESEARCH, 2019, 79 (07) : 1493 - 1506
  • [8] Artemisinin improves the efficiency of anti-PD-L1 therapy in T-cell lymphoma
    Yan, Dehong
    Zhang, Mengqi
    Adeshakin, Adeleye O.
    Wan, Xiaochun
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [9] Blockade of the Immune Checkpoint CD47 By TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma
    Han, Zhen
    Wu, Xiwei
    Yuan, Yate-Ching
    Qin, Hanjun
    Su, Chingyu
    Zain, Jasmine
    Akilov, Oleg E.
    Rosen, Steve T.
    Feng, Mingye
    Querfeld, Christiane
    BLOOD, 2022, 140 : 6376 - 6377
  • [10] Benefit with anti-PD-L1
    Diana Romero
    Nature Reviews Clinical Oncology, 2017, 14 : 71 - 71
12345